Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Novartis’ phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover

Novartis’ phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover

  • June 12, 2026

Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies about the next steps for its dystrophy prospect.

Leave A Comment

Fields (*) Mark are Required